Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Background: Aggressive disease control soon after multiple sclerosis (MS) diagnosis may prevent irreversible neurological damage, and therefore early initiation of a high-efficacy disease-modifying therapy (DMT) is of clinical relevance. Objectives: Evaluate long-term clinical outcomes in patients w...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan, Tim Spelman
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2024-01-01
Serija:	Therapeutic Advances in Neurological Disorders
Online dostop:	https://doi.org/10.1177/17562864231221331
Oznake:	Označite Brez oznak, prvi označite!